Search results
Showing 271 to 280 of 280 results for coronavirus
NICE partners with international health technology assessment bodies
Six health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.
Thousands of appointments released for the NHS without compromising safety
Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term
Starting with the end in mind - the Innovative Licensing and Access Pathway
The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.
Speaking with one language: How using a common data model might speed up decision making
The European Health Data and Evidence Network (EHDEN) project could support faster patient access to innovative medicines in areas of unmet need.
This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
More people could be treated out of hospital in the NHS's new respiratory hubs and virtual wards
Consultation launched on draft guidance for the assessment and management of acute respiratory infections in people over 16
People at risk of severe COVID-19 to have access to antiviral Paxlovid
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.
NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
We've updated our health inequalities web resource so that it maps NICE guidance to frameworks for children and young people.